Search clinical trials for: miFL bevacizumab

Total 2506 results

Sun Yat-sen University
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Outlook Therapeutics, Inc.

Completed

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Age-related Macular Degeneration | Wet Macular Degeneration | Neovascular Age-related Macular Degeneration

United States
Abramson Cancer Center of the University of Pennsylvania
Genentech, Inc.

Completed

Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer

Breast Cancer

United States
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma.

Sarcoma

Spain, Belgium, Canada, Czechia, France, Brazil, United Kingdom, Israel, Italy, Russian Federation, Netherlands, Poland, Chile, Germany
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel

Prostate Cancer

United States
University of Pennsylvania
National Eye Institute (NEI)

Completed

Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial

Age Related Macular Degeneration

United States
Translational Oncology Research International
Genentech, Inc.

Completed

Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)

Breast Cancer

United States
Medical University of Vienna

Terminated

The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion

Macular Degeneration | Vascular Endothelial Growth Factor | Regional Blood Flow

Austria
Austin Health

Unknown

Dual Targeting of Vascular Endothelial Growth Factor-A Together With Angiopoietins in Chemotherapy-naïve Metastatic Colorectal Cancer (Vengeance)

Metastatic Colorectal Cancer

Australia
Chap, Linnea I., M.D.
Genentech, Inc.

Unknown

Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study

Breast Cancer

United States
GOG Foundation
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7

United States
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Lung Adenocarcinoma | Lung Large Cell Carcinoma | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Minimally Invasive Lung Adenocarcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Lung Squamous Cell Carcinoma | Lung Adenosquamous Carcinoma

United States
Peking University Cancer Hospital & Institute

Recruiting

RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression

Fallopian Tube Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma

China
The First Affiliated Hospital of Xiamen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma | Bevacizumab | TACE | Adebrelimab | Transformation

China
Sun Yat-sen University

Not yet recruiting

TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria (B-TACE)

Hepatocellular Carcinoma by BCLC Stage

China
Second Affiliated Hospital of Nanchang University
Zhejiang University

Not yet recruiting

Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma.

Glioblastoma
Henan Provincial People's Hospital

Not yet recruiting

Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma

Recurrent Glioblastoma

China
Henan Provincial People's Hospital

Recruiting

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma

Oligodendroglioma

China
Fujian Cancer Hospital

Recruiting

TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer

Colorectal Cancer | Immunotherapy

China
University of Utah

Withdrawn

Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab

Glioblastoma Multiforme (GBM)

United States
University of Southern California

Unknown

Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)

Renal Cell Cancer

United States
Herbert Hurwitz, MD
Genentech, Inc.; Centocor, Inc.

Completed

Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors (CNTO95/Avastin)

Solid Tumors

United States
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer

Belgium, France, Germany, Italy, Spain, Australia, Canada, Czech Republic, Singapore, New Zealand, Austria, China, Netherlands, South Africa, United Kingdom, Israel, Peru, Finland, Poland, Taiwan, Sweden
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) Combined With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum

Colorectal Cancer

France
University of Chicago
Genentech, Inc.

Terminated

Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Khon Kaen University

Completed

Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy

Proliferative Diabetic Retinopathy | Vitreous Hemorrhage

Thailand
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.

Colorectal Cancer

Canada, Australia, New Zealand
Sanofi

Completed

TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer

Colorectal Cancer

United States
University of Sao Paulo

Completed

Preoperative Bevacizumab for Vitreous Hemorrhage (IBEVI)

Diabetic Retinopathy | Vitreous Hemorrhage

Brazil
Asociación para Evitar la Ceguera en México
National Council of Science and Technology, Mexico; Universidad Nacional Autonoma...

Completed

Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization

Corneal Neovascularization

Mexico
Shanghai Zhongshan Hospital

Not yet recruiting

A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma
Shanghai Minimally Invasive Surgery Center

Recruiting

Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy

Rectal Cancer | Bevacizumab | Radiotherapy | Neoadjuvant Treatment

China
Peking University

Completed

HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC

Advanced Biliary Tract Cancer

China
Hoffmann-La Roche

Completed

A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer

Colorectal Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
Fudan University

Not yet recruiting

DEBIRI Combined With Chemotherapy and Bevacizumab in the Treatment of Unresectable Colorectal Cancer Liver Metastases (DEBIRI)

Colorectal Neoplasms

China
Sun Yat-sen University

Recruiting

Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria) (BEST)

Hepatocellular Carcinoma

China
National Cancer Institute, Naples

Recruiting

Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer (ARBITRATION)

Metastatic Colorectal Cancer

Italy
Northwell Health

Suspended

Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma

Glioblastoma Multiforme | Anaplastic Astrocytoma

United States
University Hospital of Ferrara
Regione Emilia-Romagna

Completed

Single or Combined Protocols for NV-AMD

Age-Related Macular Degeneration
Genentech, Inc.

Completed

A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors

Solid Cancers
Hoffmann-La Roche

Terminated

A Genetic Substudy Associated With the Avastin (Bevacizumab) Study MO19390 in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Non-Squamous Non-Small Cell Lung Cancer

Spain
Herbert Hurwitz, MD
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific
Samsung Medical Center

Unknown

The Effect of Bevacizumab on the Trabeculectomy (bevazicumab)

Glaucoma

Korea, Republic of
University of Sao Paulo
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

Completed

Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia

Telangiectasis | Retina

Brazil
Yonsei University

Recruiting

Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases

Metastatic Colorectal Cancer

Korea, Republic of
University of Chicago
Genentech, Inc.

Completed

Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC (AVF4759)

Advanced Non-squamous Non-Small Cell Lung Cancer

United States
Austrian Breast & Colorectal Cancer Study Group
Hoffmann-La Roche

Completed

Preoperative Combined Induction Chemotherapy With Capecitabine, Oxaliplatin, Bevacizumab and Radiotherapy

Rectal Cancer

Austria
Annick Desjardins

Completed

Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)

Malignant Glioma

United States

Search clinical trials for: miFL bevacizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations